Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2020 and Highlights Recent Corporate Updates
News provided by
Share this article
Share this article
SAN DIEGO, Feb. 24, 2021 /PRNewswire/ Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced financial results for the three and twelve months ended December 31, 2020 and highlighted recent corporate updates.
Recent Corporate Updates
Pain Management Franchise
New Drug Application Resubmission for HTX-011 Under Review: The New Drug Application (NDA) resubmission for HTX-011, an investigational agent for the management of postoperative pain, submitted November 12, 2020 to the U.S. Food and Drug Administration (FDA), continues under review. The FDA set a Prescription Drug User Fee Act (PDUFA) goal date
United-kingdom
Canada
David-szekeres
Heron-biochronomer
Prnewswire-heron-therapeutics-inc
European-commission
Drug-administration
European-commission-authorization
Nasdaq
Exchange-commission
European-union
Health-canada